Sort   by:  
 Page size 
ProteomicsFucosylation of HLA-DRB1 regulates CD4+T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy: CD4+ T Cell Phosphoproteomics
Immunotherapy efficacy is limited in melanoma, and combinations of immunotherapies with other modalities have yielded limited improvements but also adverse events requiring cessation of treatment. In addition to ineffective patient stratification, efficacy is impaired by paucity of intratumoral immu...
ORGANISM(S): Homo sapiens (Human) 
2022-12-16 | PXD038065 | Pride
Phosphoproteomics Fucosylation Melanoma Cd4 t cells Immunotherapy 
ProteomicsFucosylation of HLA-DRB1 regulates CD4+T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy: HLA-DRB1 Interactomes
Immunotherapy efficacy is limited in melanoma, and combinations of immunotherapies with other modalities have yielded limited improvements but also adverse events requiring cessation of treatment. In addition to ineffective patient stratification, efficacy is impaired by paucity of intratumoral immu...
ORGANISM(S): Homo sapiens (Human) 
2022-12-16 | PXD038068 | Pride
Fucosylation Melanoma Interactome Hla-drb1 Immunotherapy 
ProteomicsFucosylation of HLA-DRB1 regulates CD4+T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy: Fucoproteomic profiling of CD4 T cells
Immunotherapy efficacy is limited in melanoma, and combinations of immunotherapies with other modalities have yielded limited improvements but also adverse events requiring cessation of treatment. In addition to ineffective patient stratification, efficacy is impaired by paucity of intratumoral immu...
ORGANISM(S): Homo sapiens (Human) 
2022-12-16 | PXD038636 | Pride
Melanoma Fucose Cd4 t cells Immunotherapy 
ProteomicsFucosylation of HLA-DRB1 regulates CD4+T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy: Fucose Click Chemistry
Immunotherapy efficacy is limited in melanoma, and combinations of immunotherapies with other modalities have yielded limited improvements but also adverse events requiring cessation of treatment. In addition to ineffective patient stratification, efficacy is impaired by paucity of intratumoral immu...
ORGANISM(S): Homo sapiens (Human) 
2022-12-16 | PXD038303 | Pride
Fucosylation Melanoma Hla-drb1 Immunotherapy 
TranscriptomicsTranscription profiling of mouse cerebral cortex using two model strains (C57BL/6 and ApoE(-/-) on the C57BL background) upon episode hypoxia treatment
Study the gene expression variation at cerebral cortex using two mouse model strains (C57BL/6 and ApoE(-/-) on the C57BL background) upon episode hypoxia treatment
ORGANISM(S): Mus musculus 
2013-01-30 | E-TIGR-135 | biostudies-arrayexpress
UnknownDomain mapping of disease mutations reveals pathogenic SORL1 variants in Alzheimer's disease.
Not available
S-EPMC12667055 | biostudies-literature
UnknownExome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer's disease.
Not available
S-EPMC9729101 | biostudies-literature
UnknownGenetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing.
Not available
S-EPMC6463297 | biostudies-literature
UnknownNew insights into the genetic etiology of Alzheimer's disease and related dementias.
Not available
S-EPMC9005347 | biostudies-literature
UnknownCommon variants in Alzheimer's disease and risk stratification by polygenic risk scores.
Not available
S-EPMC8184987 | biostudies-literature
Sort   by:  
 Page size